Diabetes

Collaboration has been the name of the game in cardiometabolic care. Here's what's going on when managing patients who have type 2 diabetes and chronic kidney disease.

Studies tie disease to higher risk of COVID-related hospitalizations and deaths

Issues with a contract manufacturer have led to limited availability for semaglutide.

New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.

The company will provide uninsured patients nationwide an avenue for getting the drug at a far more affordable price point.

More financial incentives for high-value services, greater data interoperability are needed to address problem

An analysis of the DCCT and EDIC studies provides clinicians with insights into the risk factors associated with incident cancer diagnoses among patients with type 1 diabetes.

Research examines the effect of time-restricted meals on metabolic health in patients with type 2 diabetes.

Research indicates that the risk of certain conditions becomes significantly increased following a bout of COVID-19.

Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide) are leading the way for a new crop of drugs that reduce appetite, but the cost-effectiveness is in question with many payers saying no to coverage.

The state's budget includes $100 million for the new program.

Over time, the emotional burden of managing the disease can become overwhelming.

Tirzepatide is a once-weekly subcutaneous injection to treat type 2 diabetes in conjunction with diet and exercise.

As Congress considers legislation that would cap out-of-pocket costs for insulin, Walmart and Civica Rx are taking steps that could make less expensive versions of the diabetes medication more available.

Diabetes patients with a Medicare Advantage plan had poorer health than those on fee-for-service plans

New research supports the safety of automated insulin delivery systems.

New research indicates dulaglutide is effective in improving glycemic control in pediatric patients with diabetes.

An analysis of real-world data from more than 6500 patients compared the risk of fracture for insulin, metformin, and a combination of insulin and metformin.

An analysis of the SEARCH for Youth in Diabetes describes historic and contemporary disparities in insulin pump use for pediatric type 1 diabetes based on racial/ethnic background, household income, and insurance type.

Research indicates use of the SGLT2 inhibitor could reduce risk of developing kidney stones

Rising insulin prices have led department to examine the impetus behind setting prices that many patients can't afford.

Pharmacy residents can aid in effectively improving HbA1c levels in patients.

A do-it-yourself option to replace traditional diabetes management technology is growing in popularity.

Continuous glucose monitoring has many benefits and can improve disease management in for both diabetes types.

The FreeStyle Libre 3 system, billed as the world's smallest, thinnest, and most accurate 14-day glucose sensor, received FDA clearance on May 31 and is expected to be available in participating pharmacies later this year.